Liraglutide results: what to expect and when

A daily GLP-1 injection approved for weight management and type 2 diabetes.

Also called: Saxenda, Victoza, NN2211, Xultophy component.

GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.

438 registered interventional records found before the cutoff, including planned trials and comparator arms. Selected major reports appear below; this is not a completed-trial count.

Key studies

  • Early fixed daily doses: 0.75 mg lowered HbA1c by 0.75 percentage points versus placebo. (source)
  • Higher daily dose finding: 0.65, 1.25 and 1.90 mg: −1.27, −1.69 and −1.74 percentage points, respectively. (source)
  • LEAD-1: added to glimepiride: 0.6/1.2/1.8 mg: −0.6/−1.1/−1.1%; rosiglitazone −0.4%; placebo +0.2%. (source)
  • LEAD-2: added to metformin: 0.6/1.2/1.8 mg: −0.7/−1.0/−1.0%; glimepiride −1.0%; placebo +0.1%. (source)
  • LEAD-3: monotherapy: 1.2 mg −0.84%; 1.8 mg −1.14%; glimepiride −0.51%. (source)
  • LEAD-4: metformin plus rosiglitazone: 1.2 mg −1.5%; 1.8 mg −1.5%; placebo −0.5%. (source)

Related to Liraglutide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.